LLY.NEO Eli Lilly CDR (CAD Hedged)
- Market cap
- CAD 1.74T
- P/E
- 62.5x
- P/B
- 31.12x
- ROE
- 85.5%
- Dividend yield
- 0.58%
- Fundamental score
- 2.1/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is LLY.NEO undervalued?
Graham numberThe Graham number of Eli Lilly CDR (CAD Hedged) cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Eli Lilly CDR (CAD Hedged) fundamental analysis
10 of 22 checks passedROE 2/2
High return on equity (85.5%), above 20%.
ROA 1/1
Return on assets (20.4%) is above the industry median (7.4%).
Profit Consistency 1/2
Profitable for 4 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (95.5%) is above the industry median (90.5%).
Revenue Growth 2/2
Revenue grew 31.7% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
High debt to equity (141.3%), above 100%.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
No interest expense reported.
PE vs Market 0/1
PE (63.5x) is above the market median (20.3x).
PE vs Industry 0/1
PE (63.5x) is above the industry median (25.0x).
PBV 0/1
Price to book (31.6x) is above the industry median (8.1x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 2,008.1, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
Dividend yield (0.4%) is in the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 1/1
Payout ratio is 26.1%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Eli Lilly CDR (CAD Hedged) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Eli Lilly CDR (CAD Hedged)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It …
Full company profileEli Lilly CDR (CAD Hedged) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Eli Lilly CDR (CAD Hedged) annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 28.5B | 34.1B | 45.0B | 65.2B | 85.5B |
| Gross Profit | 21.9B | 27.0B | 36.6B | 54.1B | 71.9B |
| Operating Income | 8.28B | 10.3B | 17.0B | 29.7B | 44.5B |
| EBITDA | 8.66B | 11.9B | 18.8B | 31.7B | 46.6B |
| Net Income | 6.24B | 5.24B | 10.6B | 20.6B | 29.0B |
| EPS | 6.57 | 5.83 | 12 | 23 | 33 |
| Balance Sheet | |||||
| Total Assets | 49.5B | 64.0B | 78.7B | 112B | 142B |
| Total Liabilities | 38.7B | 53.1B | 64.4B | 85.9B | 108B |
| Shareholders' Equity | 10.6B | 10.8B | 14.3B | 26.5B | 33.9B |
| Cash & Short-term Investments | 2.07B | 2.82B | 3.27B | 7.27B | 8.95B |
| Cash Flow | |||||
| Operating Cash Flow | 7.59B | 4.24B | 8.82B | 16.8B | 32.0B |
| Capital Expenditure | 2.99B | 7.39B | 8.40B | 10.8B | 17.5B |
| Free Cash Flow | 4.60B | -3.15B | 414M | 5.96B | 14.6B |
| Ratios | |||||
| ROE | 58.6% | 48.6% | 74.2% | 77.8% | 85.5% |
| ROA | 12.6% | 8.2% | 13.5% | 18.4% | 20.4% |
| Net Profit Margin | 21.9% | 15.4% | 23.5% | 31.7% | 33.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Eli Lilly CDR (CAD Hedged) dividends
- Dividend yield
- 0.58%
- Forward dividend
- 0.23 CAD
- Payout ratio
- 26.1%
- Ex-dividend date
- Feb 13, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 5.38B | 6.02 | 26.1% |
| 2024 | USD 4.68B | 5.21 | 44.2% |
| 2023 | USD 4.07B | 4.52 | 77.7% |
| 2022 | USD 3.54B | 3.72 | 56.6% |
| 2021 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Eli Lilly CDR (CAD Hedged)
Ownership data of Eli Lilly CDR (CAD Hedged) is not available yet.
Eli Lilly CDR (CAD Hedged) company profile
- Company name
- Eli Lilly CDR (CAD Hedged)
- Ticker
- LLY.NEO
- ISIN
- CA28655A1066
- Exchange
- NEO Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 47,000
- Fiscal year end
- December
- Address
- Lilly Corporate Center, Indianapolis, IN, United States, 46285
- Phone
- 317 276 2000
- Website
- lilly.com
About Eli Lilly CDR (CAD Hedged)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd; Strategic Collaboration with Eli Lilly to advance development of its myeloid engager platform for autoimmune disease, as well as Strategic partnership with NVIDIA Corporation. The company also has a research collaboration agreement with Insilico Medicine for the development of advance therapies. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Eli Lilly CDR (CAD Hedged) management
10- Mr. David A. RicksChairman, CEO & President · born 1968
- Mr. Lucas E. MontarceExecutive VP & CFO · born 1977
- Dr. Daniel M. Skovronsky M.D., Ph.D.Chief Scientific & Product Officer and President of Lilly Research Laboratories · born 1973
- Ms. Anat Hakim J.D.Executive VP, General Counsel & Secretary · born 1969
- Mr. Jacob S. Van NaardenExecutive VP & President of Lilly Oncology · born 1985
- Mr. Gordon BrooksGroup VP, Controller & Corporate Strategy
- Mr. Donald A. ZakrowskiSenior VP of Finance & Chief Accounting Officer
- Mr. Diogo RauEVP & Chief Information and Digital Officer · born 1975
- Mr. Eric DozierExecutive VP & Chief People Officer · born 1967
- Mr. Jeffrey N. SimmonsSenior VP & President of Elanco Animal Health · born 1967